Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double‐blind controlled trial
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Fatigue is a common symptom in primary biliary cirrhosis (PBC). In animal models of cholestasis, abnormalities in serotonin neurotransmission are observed with fatigue. The role of selective serotonin reuptake inhibitors in fatigue-related PBC, however, is unknown. A double-blind, placebo-controlled study design was conducted to determine the safety and efficacy of fluoxetine for the treatment of fatigue in PBC. Patients were randomized to fluoxetine, 20 mg daily, or matched placebo for 8 weeks' duration. Fatigue was assessed by the Fisk Fatigue Impact Scale (FFIS). The primary study endpoint was a > or =50% reduction in overall FFIS score at the end of treatment. Health-related quality of life (HRQL) was assessed as a secondary endpoint. Among 220 consecutively screened patients, only 18 (9%) eligible individuals were randomized to fluoxetine (n=10) or placebo (n=8) for 8 weeks. Baseline variables including median FFIS scores (52 vs 42; P=0.21) were similar between treatment arms (P > 0.05). After 8 weeks of therapy, no statistically significant change in median FFIS score was observed in the fluoxetine group. Median FFIS score in the placebo group was reduced (42 to 28), but not statistically significant. No difference in HRQL was observed between treatment arms after 8 weeks. Fourteen (78%) patients completed therapy, while four (22%) individuals withdrew from the trial. Three of the four patients had drug-related adverse events with fluoxetine. In this study, fluoxetine did not improve fatigue in PBC and was associated with adverse events.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Altered serotonin neurotransmission may mediate fatigue in chronic liver disease (183) ; however, ondansetron, an antagonist to serotonin receptor, did not relieve fatigue in a clinical trial.(184)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [184]
Citations
Cites
The CES-D Scale: A Self-Report Depression Scale for Research in the General Population
Radloff, L. S. (1977) · Applied Psychological Measurement · doi:10.1177/014662167700100306 · Cited by 53,267 · cited 7×
“%) individuals were not randomized based on scores ≥16 points on the CES-D questionnaire.”
MethodInfluentialMeasuring the Functional Impact of Fatigue: Initial Validation of the Fatigue Impact Scale
Fisk, J. D., Ritvo, P. G., Ross, L., Haase, D. A., Marrie, T. J., & Schlech, W. F. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.supplement_1.s79 · Cited by 1,541 · cited 1×
“Baseline fatigue severity was determined in all randomized patients with the Fisk Fatigue Impact Scale (FFIS) [22].”
MethodDEMITRACK, M. A., DALE, J. K., STRAUS, S. E., LAUE, L., LISTWAK, S. J., KRUESI, M. J. P., CHROUSOS, G. P., & GOLD, P. W. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-6-1224 · Cited by 727 · cited 1×
“The recognition of defective central serotonin neural activity is also observed with nonhepatic disorders such as chronic fatigue syndrome [27].”
BackgroundYounossi, Z. M., Guyatt, G., Kiwi, M., Boparai, N., & King, D. (1999) · Gut · doi:10.1136/gut.45.2.295 · Cited by 670 · cited 9×
“Springer Health-related quality-of-life assessment was performed with the Chronic Liver Disease Questionnaire (CLDQ) [23].”
MethodInfluentialThe presentation and diagnosis of 100 patients with primary biliary cirrhosis
Sherlock, S., & Scheuer, P. J. (1973) · New England Journal of Medicine · doi:10.1056/nejm197309272891306 · Cited by 504 · cited 1×
“Bile duct injury from portal and periportal inflammation often results in progressive fibrosis and eventual cirrhosis [1].”
BackgroundUrsodiol for the Long-Term Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Poupon, R., & Balkau, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301903 · Cited by 497
Ursodeoxycholic acid in the treatment of primary biliary cirrhosis
Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90021-3 · Cited by 487
Self-citationSWAIN, M. G. (2000) · Clinical Science · doi:10.1042/cs0990001 · Cited by 383 · cited 1×
“Both serotonergic and noradrenaline pathways have been implicated [26].”
BackgroundPrince, M., Chetwynd, A., Newman, W., Metcalf, J. V., & James, O. F. W. (2002) · Gastroenterology · doi:10.1053/gast.2002.36027 · Cited by 348
Christensen, E., Crowe, J., Doniach, D., Popper, H., Ranek, L., Rodés, J., Tygstrup, N., & Williams, R. (1980) · Gastroenterology · doi:10.1016/0016-5085(80)90571-5 · Cited by 273
Cited by
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Self-citationLindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913
“(184) Fluoxetine, a selective serotonin reuptake inhibitor, also did not improve fatigue.(185) Patients with PBC-related fatigue have excessive daytime sleepiness.”
BackgroundSelf-citationCarey, E. J., Ali, A. H., & Lindor, K. D. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00154-3 · Cited by 735
Self-citationHohenester, S., Oude-Elferink, R. P. J., & Beuers, U. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0164-5 · Cited by 179
“The selective serotonin reuptake inhibitors fluvoxamine and fluoxetine also failed to exert beneficial effects on fatigue in this patient group [311, 312].”
BackgroundPrimary biliary cholangitis: Epidemiology, prognosis, and treatment
Trivella, J., John, B. V., & Levy, C. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000179 · Cited by 159
Liver transplantation in PBC and PSC: Indications and disease recurrence
Carbone, M., & Neuberger, J. (2011) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2011.02.007 · Cited by 93
Gossard, A. A., & Talwalkar, J. A. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2013.09.002 · Cited by 78
Self-citationKhanna, A., Jopson, L., Howel, D., Bryant, A., Blamire, A., Newton, J. L., & Jones, D. E. (2019) · Hepatology · doi:10.1002/hep.30099 · Cited by 75
“Neither of these trials, which explore the use of Fluoxetine and Modafanil, showed evidence of benefit.(8,9) At the time of the design of this trial, evidence was emerging to suggest that the anti-CD20 biological agent rituximab was effective for the reduction of fatigue in a number of immune conditions, including pri…”
BackgroundSilveira, M. G., Gossard, A. A., Stahler, A. C., Jorgensen, R. A., Petz, J. L., Ali, A. H., & Lindor, K. D. (2017) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000387 · Cited by 64
Self-citationGender specific medicine in liver diseases: A point of view
Durazzo, M., Belci, P., Collo, A., Prandi, V., Pistone, E., Martorana, M. C., Gambino, R., & Bo, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i9.2127 · Cited by 63
Primary Biliary Cholangitis and Primary Sclerosing Cholangitis
Yokoda, R. T., & Carey, E. J. (2019) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000268 · Cited by 60
Fatigue in primary biliary cirrhosis
Abbas, G., Jorgensen, R. A., & Lindor, K. D. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.62 · Cited by 60
Self-citationPharmacological interventions for primary biliary cholangitis
Saffioti, F., Gurusamy, K. S., Eusebi, L. H., Tsochatzis, E., Davidson, B. R., & Thorburn, D. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011648.pub2 · Cited by 53
Beery, R. M. M., Vaziri, H., & Forouhar, F. (2014) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2014.00024 · Cited by 58
“[97] Talwalkar JA, Donlinger JJ, Gossard AA, Keach JC, Jorgensen RA, Petz JC, et al.”
BackgroundSymptoms of PBC – Pathophysiology and management
Khanna, A., Leighton, J., Wong, L. L., & Jones, D. E. (2018) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2018.06.007 · Cited by 50
Clinical features and management of primary biliary cirrhosis
Crosignani, A. L., Battezzati, P. M., Invernizzi, P., Selmi, C. F., Prina, E., & Podda, M. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.3313 · Cited by 52
Gan, S. I., de Jongh, M., & Kaplan, M. M. (2008) · Digestive Diseases and Sciences · doi:10.1007/s10620-008-0613-3 · Cited by 47
“Attempts to treat PBC-related fatigue with a variety of medications, including ursodeoxycholic acid [6], fluoxetine [7], fluvoxamine [8], colchicine [9], methotrexate [10], and ondansetron [11], have not been successful [12].”
BackgroundTreatment of Fatigue in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis
Lee, J. Y., Danford, C. J., Trivedi, H. D., Tapper, E. B., Patwardhan, V. R., & Bonder, A. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-5457-5 · Cited by 47
Review article: pathophysiology and management of primary biliary cholangitis
Leung, K. K., Deeb, M., & Hirschfield, G. M. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16023 · Cited by 40
Medical Treatment of Cholestatic Liver Disease
Paumgartner, G., & Pusl, T. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.11.013 · Cited by 39
Understanding fatigue in primary biliary cholangitis: From pathophysiology to treatment perspectives
Lynch, E. N., Campani, C., Innocenti, T., Dragoni, G., Biagini, M. R., Forte, P., & Galli, A. (2022) · World Journal of Hepatology · doi:10.4254/wjh.v14.i6.1111 · Cited by 39
Primary biliary cirrhosis in adults
Momah, N., & Lindor, K. D. (2014) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2014.888950 · Cited by 35
“reuptake inhibitor nor ondansetron, a serotonin receptor antagonist, has been helpful in improving fatigue in individuals with PBC [43,44].”
BackgroundSelf-citationBjörnsson, E., Kalaitzakis, E., Neuhauser, M., Enders, F., Maetzel, H., Chapman, R. W., Talwalkar, J., Lindor, K., & Jorgensen, R. (2010) · Liver International · doi:10.1111/j.1478-3231.2009.02160.x · Cited by 33
Self-citationHoudenhove, B. V., Verheyen, L., Pardaens, K., Luyten, P., & Wambeke, P. V. (2007) · Clinical Rehabilitation · doi:10.1177/0269215507080769 · Cited by 35
Fatigue in chronic liver disease patients: prevalence, pathophysiology, and management
Kośnik, A., & Wójcicki, M. (2022) · Gastroenterology Review · doi:10.5114/pg.2022.114594 · Cited by 30
“Fluvoxamine [43] and fluoxetine [44] have also been shown to be ineffective in patients with PBC with no concomitant depression.”
BackgroundPatel, A., Tapper, E. B., Kanwal, F., Woodrell, C. D., Hansen, L., Lai, J. C., Rogal, S. S., McDermott, C. L., Rakoski, M. O., & Ufere, N. N. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000135 · Cited by 24
“Chronic pain can be characterized using 3 mecha nistic descriptors: nociceptive, neuropathic, and SYMPTOM-FOCUSED TRIALS AIMED AT PATIENTS WITH CIRRHOSIS | 7 TABLE 4 Key symptom targets, measures, and psychometric properties Symptom Outcome Measure Prior use in cirrhosis MCID or MDC [population used to establish it] M…”
InfluentialCerri, G., Cocchi, C. A., Montagna, M., Zuin, M. G., Podda, M., Cavallari, P., & Selmi, C. F. (2010) · Clinical Neurophysiology · doi:10.1016/j.clinph.2009.12.040 · Cited by 25
Fatigue in cholestatic liver disease: Is it all in the mind?
Jones, D. E. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.03.006 · Cited by 21
Emerging drugs for the treatment of Primary Biliary Cholangitis
Ali, A. H., Tabibian, J. H., Carey, E. J., & Lindor, K. D. (2016) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2016.1150999 · Cited by 19
“fluoxetine do not improve fatigue in PBC.[231,232] Pilot clinical trials of modafinil (a stimulant) in PBC patients having”
BackgroundSelf-citationChascsa, D. M. H., Lai, J. C., Dunn, M. A., Montaño‐Loza, A. J., Kappus, M. R., Dasarathy, S., & Carey, E. J. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-5271-5 · Cited by 18
Koc, O. M., Toussaint, A. C., Untas, A., Milkiewicz, P., Ytting, H., Buck, L., Jones, D. E., Hirschfield, G. M., Leburgue, A., Schramm, C., et al. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00257-2 · Cited by 19
Current and promising therapy for primary biliary cholangitis
Gossard, A. A., & Lindor, K. D. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1601701 · Cited by 16
“a stimulant, have proven disappointing [44,45].”
Self-citationCharatcharoenwitthaya, P., Talwalkar, J. A., Angulo, P., Gossard, A. A., Keach, J. C., Petz, J. L., Jorgensen, R. A., & Lindor, K. D. (2009) · Digestive Diseases and Sciences · doi:10.1007/s10620-009-0744-1 · Cited by 13
“The pathogenesis of fatigue in PBC remains unclear and no effective therapy in ameliorating this debilitating symptom exists [35–38].”
Self-citationA study of Fatigue, Depression and Sleep Disorders in Patients with Chronic Liver Disease
Ji-Suk, K., Hong, H.-S., & Na, Y.-K. (2012) · Journal of Korean Biological Nursing Science · doi:10.7586/jkbns.2012.14.1.1 · Cited by 12
“더 욱이 만성 간 질환에서 나타나는 피로의 치료를 위한 방법으로 항 우울 약물의 사용은 효과가 없는 것으로 나타나(Talwalkar et al., 2006), 만성 간 질환자의 피로, 우울 및 수면장애를 개선하는 데 약 물치료에 의존하기보다 심신의 안정과 비약물 치료프로그램을 개 발하여 관리하는 것도 고려될 필요가 있을 것이다.”
Managing Sleep Disturbances in Cirrhosis
Zhao, X., & Wong, P. Y. N. (2016) · Scientifica · doi:10.1155/2016/6576812 · Cited by 11
“Treatment of fatigue in PBC with fluvoxamine [49], fluoxetine [50], ondansetron [51], and several other medications has been unsuccessful.”
BackgroundManagement of Fatigue in Primary Biliary Cholangitis
Khanna, A., Hegade, V. S., & Jones, D. E. (2019) · Current Hepatology Reports · doi:10.1007/s11901-019-00458-0 · Cited by 11
Ahmed, A., & Mayo, M. J. (2014) · Clinical gastroenterology · doi:10.1007/978-1-4939-1013-7_9 · Cited by 11
Update on Emerging Treatment Options for Primary Biliary Cholangitis
Aguilar, M. T., & Chascsa, D. M. H. (2020) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s205431 · Cited by 11
Pathogenesis and management of fatigue in primary biliary cholangitis
Shamshtein, D., & Liwinski, T. (2022) · Fatigue Biomedicine Health & Behavior · doi:10.1080/21641846.2022.2034473 · Cited by 10
“Furthermore, no benefit could be shown in randomized controlled trials (RCTs) using selective serotonin reuptake inhibitors (SSRIs) in PBC-associated fatigue [56, 57].”
BackgroundDaza, J., Montagut, N. E., Kautz, A., Langenbacher, D., Hetjens, M., Siegel, F. P., Ebert, M. P., & Teufel, A. (2025) · Digestive Diseases · doi:10.1159/000543229 · Cited by 9
Care of the Cholestatic Patient
Gossard, A. A. (2012) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.11.005 · Cited by 11
“In PBC, fluoxetine was studied and was not helpful.(57)”
BackgroundSelf-citationPrimary biliary cholangitis: advances in understanding and management
Smith, A., Giles, B., & Aspinall, R. (2022) · British Journal of Hospital Medicine · doi:10.12968/hmed.2021.0450 · Cited by 6
Díaz‐González, Á., Molera, C., Gómez-Domínguez, E., Muñoz‐Bartolo, G., Ampuero, J., Fernández‐Rodríguez, C., Quintero, J., Molina, E., Salcedo, M., Olveira, A., et al. (2025) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2026.502629 · Cited by 3
Pruritus, Fatigue, Osteoporosis and Dyslipoproteinemia in Pbc Patients: A Clinician’s Perspective
Dražilová, S., Koky, T., Macej, M., Janíčko, M., Simkova, D., Tsedendamba, A., Комарова, С. Г., & Jarčuška, P. (2024) · Gastroenterology Insights · doi:10.3390/gastroent15020030 · Cited by 4
Fluyau, D., Kailasam, V. K., Kim, P., & Revadigar, N. (2025) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000585 · Cited by 3
Untas, A., Goffette, C., Flahault, C., Vioulac, C., Chazouillères, O., Soret, P., Belkacem, K. B., Gaouar, F., Bernard, N., Rousseau, A., et al. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003639 · Cited by 5
Tanaka, A., Takahashi, H., Nezu, S., Ueno, Y., Kikuchi, K., Shibuya, A., Ohira, H., Zeniya, M., Montali, L., Invernizzi, P., et al. (2009) · Kanzo · doi:10.2957/kanzo.50.51 · Cited by 2
Jorgensen, R. A. (2010) · University of Minnesota Digital Conservancy (University of Minnesota) · Cited by 3
Self-citationWhat Do We Know About the Symptoms and Palliative Care Needs of People Affected by Liver Disease?
Rakoski, M. O., Hansen, L., Verma, M., & Woodrell, C. D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-84702-5.00044-0 · Cited by 1
Trivella, J. P., & Levy, C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-26710-9.00018-3 · Cited by 1
Pharmacological treatments for primary biliary cirrhosis: a network meta-analysis
Gurusamy, K. S., Tsochatzis, E. A., Davidson, B. R., & Thorburn, D. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011648 · Cited by 1
Dancygier, H. (2009) · Springer eBooks · doi:10.1007/978-3-642-04519-6_19
Autoimmune Liver Diseases: Primary Biliary Cholangitis
Ali, A. H., Carey, E. J., & Lindor, K. D. (2016) · Springer eBooks · doi:10.1007/978-3-319-30103-7_16
Self-citation[Research advances of autoimmune liver diseases in 2018].
Chen, Y., Wang, Q. X., & Ma, X. (2019) · PubMed · doi:10.3760/cma.j.issn.1007-3418.2019.01.005
Advances in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis
Sandhu, S., & Goel, A. (2026) · Seminars in Liver Disease · doi:10.1055/a-2952-2261
Fatigue, weakness, and sleep disturbances in liver disease: Diagnosis and patient management
Raikhelson, K. L., Poluektov, M. G., Petelin, D. S., & Sheptulina, A. F. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-315
Metadata
- Authors
- Talwalkar, J. A., Donlinger, J. J., Gossard, A. A., Keach, J. C., Jorgensen, R. A., Petz, J. C., & Lindor, K. D.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Talwalkar, Jayant A.
- ORCID
- Lindor, Keith D.
- Venue
- Digestive Diseases and Sciences
- Published
- 2006-10-20
- Volume
- 51
- Issue
- 11
- Pages
- 1985-1991
- ISSN
- 0163-2116 (ISSN-L)
- 1573-2568
- OpenAlex
- W2024885291
- Cited by
- 54
- References
- 35
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 2 · 2023: 3 · 2022: 4 · 2020: 2 · 2019: 4 · 2018: 4 · 2017: 1 · 2016: 4 · 2015: 2 · 2014: 3 · 2013: 1 · 2012: 2
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Digestive Diseases and Sciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Psychiatry and Mental health › Fibromyalgia and Chronic Fatigue Syndrome Research
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- fluoxetine, primary biliary cirrhosis, fatigue, selective serotonin reuptake inhibitors, serotonergic neurotransmission, cholestasis, health-related quality of life, drug adverse events
- MeSH terms
- Adolescent, Adult, Aged, Double-Blind Method, Fatigue, Fluoxetine, Humans, Liver Cirrhosis, Biliary, Middle Aged, Prospective Studies, Quality of Life, Treatment Outcome, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.